In a research report released today, Wedbush analyst David Nierengarten reiterated an Outperform rating on Epizyme (NASDAQ:EPZM) with a $52 price target, following the company’s second-quarter financial results and update on …
For the first time, Dendreon Corp. (DNDN) acknowledged the magnitude of the risk its 2016 convertible debt has on shareholders.
In a research note published today, Wedbush analyst David Nierengarten reiterated an Outperform rating on NPS Pharmaceuticals (NPSP) with a $44 price target, ahead of NPSP’s upcoming second quarter …
The FDA granted full approval today to Pharmacyclics’ (PCYC) Imbruvica to treat Chronic Lymphocytic Leukemia (CLL) and as front-line therapy to treat CLL patients with …
In a research note published today, Wedbush analyst David Nierengarten reiterated an Outperform rating on Pharmacyclics (PCYC), with a $225 price target, following today’s news that PCYC and Janssen …
In a research note published July 18, Wedbush analyst David Nierengarten reiterated an Outperform rating on Anacor Pharmaceuticals (ANAC) and raised his price …
In a research note released yesterday, Wedbush analyst David Nierengarten reiterated an Outperform rating on Anacor Pharmaceuticals (ANAC) with a price target of …
In a research note issued earlier today, Wedbush analyst David Nierengarten maintained an Outperform and boosted his price target on Applied Genetic Technologies (AGTC) to $36.00 (from $24) …
